Protein kinase activity decreases with higher Braak stages of Alzheimer’s disease pathology
Manuscript Number:
15-0429R2
Author(s):
Elisabeth Coart, Leandro Garcia Barrado, Riet Hilhorst, Jeroen J.M. Hoozemans, Faris Naji, Andrea F.N. Rosenberger, Annemieke J. Rozemuller, Philip Scheltens, Wiesje M. van der Flier, Saskia M. van der Vies
Disclosures
Elisabeth Coart
Nothing to Disclose
Leandro Garcia Barrado
Nothing to Disclose
Riet Hilhorst
Nothing to Disclose
Jeroen J.M. Hoozemans
Patents/Royalties
Patents:
- Title: Measuring protein kinase activity in a cerebrospinal fluid comprises obtaining sample of cerebrospinal fluid, incubating the sample with ATP on an array of substance, and obtaining a detectable phosphorylation profile. Patent Number: WO2009130320-A2. Inventors: DE WIJN R, HILHORST M H, HOOZEMANS J J M, VAN DER VIES S M
- Title: Use of inhibitors of interleukin-1 receptor-associated protein kinase family for treating neurological disorders e.g. Alzheimer's disease, Huntington's disease, Creutzfeldt-Jakob disease, other prion diseases and multiple sclerosis. Patent Number: EP2243481-A1; WO2010121834-A2; WO2010121834-A3. Inventors: HILHORST M H; HOOZEMANS J J M; VAN DER VIES S M
Faris Naji
Nothing to Disclose
Andrea F.N. Rosenberger
Nothing to Disclose
Annemieke J. Rozemuller
Nothing to Disclose
Philip Scheltens
Consulting Fees:
Dr Scheltens has received grant support (for the institution) from GE Healthcare, Danone Research, Piramal and MERCK. In the past 2 years he has received consultancy/speaker fees (paid to the institution) from Lilly, GE Healthcare, Novartis, Forum, Sanofi, Nutricia, Probiodrug and EIP Pharma.